Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

Moderna Seeks US Approval of Second Covid Booster

Moderna announced Thursday it had asked the United States drug regulator for emergency authorization for a second booster shot of the company's Covid-19 vaccine for all adults. The request to the US Food and Drug Administration (FDA) would "allow for a fourth dose of our #COVID19 vaccine in adults 18…

Asharq Al-Awsat

Carcinogenic chemical benzene found in hundreds of US personal care products

Independent lab found the chemical in more than a quarter of items it tested – sometimes at levels considered ‘life threatening’

The Guardian - US

Moderna asks FDA to authorize additional booster shot for all adults

The request is much broader than Pfizer's, which sought to authorize a second booster for people over 65.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

OPNT: Data from OPNT003 Pharmacodynamic Trial in 2Q22…

By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT

Benzinga

BLRX: 2021 Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT

Benzinga

RVPH: 2021 Results

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT

Benzinga

Why Are TC Biopharm Shares Trading Higher Today

The FDA has granted Orphan Drug designation to TC Biopharm Ltd's (NASDAQ:TCBP) lead product OmnImmune for use in Acute Myeloid Leukemia. After reviewing the Phase 1b/2a trial results in relapsed/refractory AML patients, the FDA approved the Company's application for Orphan Drug Status. "We look forward to the advancement of OmnImmune® in the Phase 2b/3…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions

The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ: AQST) AQST-109 for allergic reactions. AQST-109 is an orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis.

Benzinga

FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease

InflaRx N.V. (NASDAQ: IFRX) has

Benzinga

As abortion pills take off, some states move to curb them

In June, the U.S. Supreme Court is expected to weaken or topple its nearly 50-year-old abortion rights decision, Roe v. Wade, giving states wide latitude to restrict the procedure.

Tribune News Service

FDA Clears AbbVie's Rinvoq For Moderate To Severe Active Ulcerative Colitis

The FDA approved AbbVie Inc's (NYSE:ABBV) Rinvoq (upadacitinib) for adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers. This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from…

Benzinga

80 Biggest Movers From Yesterday

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares gained 86.7% to close at $0.5150 on Wednesday after the company announced FDA clearance of its IND for SON-1010 for the treatment of advanced solid tumors.

Benzinga

Second COVID-19 booster shot does little to stop omicron, study finds

Israeli health care workers who were boosted with a fourth shot of COVID-19 vaccine at the height of the omicron wave were only marginally more protected against reinfection than their peers who had received three jabs of vaccine, researchers reported Wednesday.

Los Angeles Times

$FDA Lifts Clinical Hold On Aprea's Relapsed/Refractory Blood Cancer Studies$

FDA Lifts Clinical Hold On Aprea's Relapsed/Refractory Blood Cancer Studies

Aprea Therapeutics Inc (NASDAQ: APRE) can resume testing its eprenetapopt after a string of clinical holds on the therapy in August 2021. The Company plans to study the drug in new trials across various myeloid and lymphoid malignancies.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Medtronic's US Trial Of GI Genius Endoscopy Module Reduces Missed Colorectal Polyps By 50%

Medtronic plc (NYSE:MDT) announced final findings from a study that confirmed the effectiveness of the GI Genius intelligent endoscopy module. GI Genius uses AI to aid in detecting colorectal polyps during colonoscopy, potentially helping to prevent colorectal cancer (CRC). The study published in Gastroenterology found that the use of GI Genius in conjunction with…

Benzinga

FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer

The FDA has lifted the clinical hold on AIM ImmunoTech Inc's (NYSE:AIM) investigational new drug (IND) application for a Phase 2 study of Ampligen for locally advanced pancreatic cancer (AMP-270). The AMP-270 clinical trial's primary objective compares the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced…

Benzinga

Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors

The FDA has cleared Adagene Inc's (NASDAQ:ADAG) Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with Merck & Co Inc's (NYSE:MRK) Keytruda (pembrolizumab). The global trial (ADG126-P001 / KEYNOTE-C98) will evaluate patients with advanced/metastatic solid tumors. The ADG126-P001 trial is expected to dose the first patients soon. The trial is…

Benzinga

Sonnet Shares Surge As FDA Clears Its First Human Trial For Solid Tumor Candidate

The FDA has signed off Sonnet BioTherapeutics Holdings Inc's (NASDAQ:SONN) Investigational New Drug (IND) application for SON-1010, a proprietary version of Interleukin 12 (IL-12) configured using Sonnet's Fully Human Albumin Binding (FHAB) technology. Sonnet will initiate its First-in-Human Phase 1 trial in adult oncology patients in Q2 of 2022. The study will establish…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers

The FDA has signed off Iovance Biotherapeutics Inc's (NASDAQ:IOVA) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ:CLLS). A clinical study of IOV-4001 in patients with metastatic melanoma…

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Manufacturing Bottlenecks Hit Launch Of Talis' FDA-Approved COVID-19 Test

Talis Biomedical Corp (NASDAQ: TLIS) said that it had

Benzinga

Pfizer-BioNTech Seek FDA Approval For Second COVID-19 Booster In Elderly Population

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) filed an application with the

Tribune News Service

Pfizer asks FDA to clear another booster for older adults

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional COVID-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes.

Benzinga

FDA Recommends At Least 15 years Of Follow-Up For Genome Editing Product Trials

The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products.

Benzinga

Smart For Life Agrees To Acquire Vitamin & Supplement Company Ceautamed For Undisclosed Sum

Smart For Life Inc (NASDAQ:SMFL) has agreed to acquire the vitamin and supplement company Ceautamed Worldwide LLC and its affiliates, Wellness Watchers Global LLC and Greens First Female LLC. The financial terms of the transaction were not disclosed. Ceautamed, based in Florida, is principally engaged in the development and distribution of nutritional products, including antioxidant…

1 … 262 263 264 265

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.